Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C

doi:10.4254/wjh.v9.i7.352

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8863)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

627

WORD

294

HTML

4921

Figures (1-1)

157

Tables (1-4)

190

Sum=6189

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1267

Download

1407

Sum=2674

Mar 8, 2017 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (45)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Mar 8, 2017; 9(7): 352-367
Published online Mar 8, 2017. doi: 10.4254/wjh.v9.i7.352

Table 4 Studies evaluating the effects of direct acting antivirals in liver transplant recipients

Ref.	HCV genotype	Fibrosis stage	Treatment	SVR12 rate	Observed improvement
Charlton et al[98], 2015	Cohort B	No cirrhosis: 111/229 (48.5%)	LDV/SOF + RBV 12 or 24 wk	No cirrhosis:	-
	G1a: 164/229 (71.6%)	Child A: 51/229 (22.3%)		12 wk 53/55 (96) 24 wk 55/56 (98)
	G1b: 63/229 (27.5%)	Child B: 52/229 (22.7%)		Child A:
	G4: 2/229 (0.9%)	Child C: 9/229 (3.9%)		12 wk 25/26 (96%)
		FCH: 6/229 (2.6%)		24 wk 24/25 (96%)
				Child B:
				12 wk 22/26 (85%)
				24 wk 23/26 (88%)
				Child C:
				12 wk 3/5 (60%)
				24 wk 3/4 (75%)
				FCH:
				12 and 24 wk 100%
Manns et al[101], 2016	Cohort B	No cirrhosis: 101/226 (44.7%)	LDV/SOF + RBV 12 or 24 wk	Genotype 1:	MELD improved in 58%
	G1a: 113/226 (50%)	Child A: 71/226 (31.4%)		No cirrhosis: 12 wk: 42/45 (93%)
	G1b: 86/226 (38%)	Child B: 40/226 (17.7%)		24 wk: 44/44 (100%)	Child B to A: 52%
	G4: 27/226 (12%)	Child C: 9/226 (4%)		Child A:	Child C to B: 60%
		FCH: 5/226 (2.2%)		12 wk: 30/30 (100%)
				24 wk: 27/28 (96%)
				Child B:
				12 wk: 19/20 (95%)
				24 wk: 20/20 (100%)
				Child C:
				12 wk: 1/2 (50%)
				24 wk: 4/5 (80%)
				FCH:
				12 and 24 wk: 100%

				Genotype 4:
				No cirrhosis:
				12 and 24 wk 100%
				Child A:
				12 wk 3/4 (75%)
				24 wk 100%
				Child B:
				12 and 24 wk 100%
				Child C:
				12 wk 0%
Poordad et al[100], 2016	G1a: 31/53 (58.5%)	F0: 6	DCV/SOF + RBV 12 and 24 wk	50/53 (94%)	-
	G1b: 10/53 (18.9%)	F1: 10
	G2: 0	F2: 7
	G3: 11/53 (20.7%)	F3: 13
	G4: 0	F4: 16
	G6: 1/53 (1.9%)	ND: 1
Brown et al[111], 2016	G1a: 87/151 (57.6%)	Cirrhosis: 97/151 (64.2%)	SMV/SOF ± RBV	133/151 (88%)	-
	G1b: 42/151 (27.8%)			SMV/SOF 105/119 (88%)
	G1 (unspecified): 22/151 (14.6%)			SMV/SOF + RBV 28/32 (88%)

LDV: Ledipasvir; SOF: Sofosbuvir; RBV: Ribavirin; DCV: Daclatasvir; SMV: Simeprevir; RVR: Rapid virological response (HCV-RNA < 15 UI after 4 wk of treatment); EVR: Early virological response (HCV-RNA < 15 UI after 12 wk of treatment); GRZ: Grazoprevir; ELB: Elbasvir; VEL: Velpatasvir; FCH: Fibrosing cholestatic hepatitis; HCV: Hepatitis C virus.

Citation: Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367
URL: https://www.wjgnet.com/1948-5182/full/v9/i7/352.htm
DOI: https://dx.doi.org/10.4254/wjh.v9.i7.352